Opus Genetics Inc expected to post a loss of 20 cents a share - Earnings Preview

Opus Genetics

08/08/2025 18:58

Opus Genetics Inc IRD.OQ IRD.O is expected to  show a rise in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2025

The Durham North Carolina-based  company is expected to report a 263.7% increase in revenue to $4.045 million from $1.11 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Opus Genetics Inc is for a loss of 20 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Opus Genetics Inc is $6.00, about 81.8% above its last closing price of $1.09

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.26
-0.25
-0.24
Beat
4
Dec. 31 2025
-0.26
-0.22
Beat
14.3
Sep. 30 2024
-0.25
-0.24
-0.29
Missed
-22.1‚Äč
Jun. 30 2024
-0.28
-0.25
-0.30
Missed
-17.6
‚Äč‚ÄčMar. 31 2024
-0.11
-0.13
-0.29
Missed
-116.4
Dec. 31 2023
-0.03
-0.05
-0.21
Missed
-300‚Äč
Sep. 30 2023
-0.24
-0.22
0.25
Beat
212.6
Jun. 30 2023
-0.25
-0.23
-0.24
Missed
-6.2

This summary was machine generated August 8 at 17:57 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)